市場調查報告書

頭孢菌素劑的全球市場 - 各世代、給藥途徑、藥物、地理的成長率,趨勢及預測(2018年∼2023年)

Cephalosporin Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391378
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
Back to Top
頭孢菌素劑的全球市場 - 各世代、給藥途徑、藥物、地理的成長率,趨勢及預測(2018年∼2023年) Cephalosporin Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年04月01日內容資訊: 英文 112 Pages
簡介

全球頭孢菌素劑市場,預計從2018年到2023年的預測期間內以約3.5%的年複合成長率成長。頭孢菌素劑,屬於殺菌性β-內醯胺抗生素類,為了防止細菌的增生透過阻礙細胞牆合成。由於人口的增加,經濟發展,醫療費,感染疾病的流行等,預計在預測期間中亞太地區在市場上具優勢。

本報告提供全球頭孢菌素劑市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品與服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會及挑戰分析(DROC)

  • 市場成長要素
    • 各種適應症的抗菌藥的需求高漲
    • 企業的聯合使研究開發活動活性化
    • 感染疾病的流行
    • 聯合治療的使用增加
  • 市場阻礙因素
    • 嚴格的法規指南
    • 弱的開發平台分子
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各世代
    • 第1代
    • 第2代
    • 第3代
    • 第4代
    • 第5代
  • 各給藥途徑
    • 口服
    • 注射劑
  • 藥物的各類型
    • 品牌
    • 非專利
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Abbott
  • Astellas Pharma Inc.
  • Baxter International
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Teva Pharmaceuticals 等

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52448

Market Overview

  • The major factors for the growth of the cephalosporin drugs market include the rising demand for anti-microbial in various indications, rising prevalence of infectious diseases, and increasing use of combination therapies.
  • Most of the small companies out-license the products after taking them through the early clinical development phase. These agreements usually include one-time payment for obtaining the rights, in addition to the milestone payments on completing designated developmental phase and royalties on sales. There are over 50 cephalosporin drugs that have been approved in the past five decades, and almost half of them are for the antibacterial activity. However, new cephalosporins (classified as the fifth-generation), which are used for the treatment of serious gram-negative bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA), were recently approved.
  • Manufacturers are involved in the development of new drugs to fight against anti-microbial resistance. The complexity and diversity of resistance mechanisms have defined the need for new and improved B-lactam antibiotics. Additionally, the companies are involved in the strategic development of new products, for example, in 2017, Shionogi & Co. Ltd collaborated with the F. Hoffmann-La Roche Ltd for the development and commercialization of baloxavir marboxi.
  • Thus, owing to the all above-mentioned factors the cephalosporin drugs market is expected to witness high growth over the forecast period.

Scope of the Report

As per the scope of this report, cephalosporins are part of the beta-lactams group and work by interfering with the synthesis of the bacterial cell wall. Some may be given orally, but most are given by injection. They are typically the second choice antibiotic, their main uses are in pneumonia, septicemia, meningitis, sinusitis, and UTIs treatment. Despite their second-line usage, cephalosporins have a broader spectrum of activity and are more potent than penicillin.

Key Market Trends

The Fifth-generation Segment is Expected to Account for the Largest Market Share During the Forecast Period

The fifth-generation cephalosporins were developed in the lab to specifically target resistant strains of bacteria. In particular, ceftobiprole is effective against methicillin-resistant staphylococcus aureus (MRSA). These agents are sometimes referred to as the advanced generation, rather than fifth-generation cephalosporins. Cephalosporins exhibit side effects similar to penicillin, and drug-allergy and hypersensitivity. Cephalosporins, in general, have been associated with little hepatotoxicity and rare instances of drug-induced liver injury. The fifth-generation cephalosporins include Ceftobiprole, Ceftaroline, and Ceftolozane. Ceftobiprole has powerful antipseudomonal characteristics and appears to be less susceptible to the development of resistance. Ceftaroline has also been described as the "fifth-generation" cephalosporin, but does not have the antipseudomonal or VRE coverage of ceftobiprole. The market for Ceftolozane is growing at a good pace, as it has opened gates for an alternative for the treatment of complicated intra-abdominal infections (CIAI) and complicated urinary tract infections (CUTI). Furthermore, Ceftolozane is combined with the B-lactamase inhibitor tazobactam, as multi-drug resistant bacterial infections generally exhibit resistance to all B-lactam antibiotics, unless this enzyme is inhibited. Hence, the increase in the use of combination therapies is expected to drive the market during the forecast period.

Asia-Pacific is Expected to be the Fastest Growing Segment in the Global Market

Asia-Pacific is expected to dominate this market, due to the high prevalence of infectious diseases, increasing healthcare expenditure, and a large population base. Furthermore, the demand for better healthcare infrastructure and government initiatives is expected to help the growth of the market in this region. As per the statistics published by the World Health Organization (WHO) TB statistics for India for 2016, an estimated incidence of tuberculosis (TB) is 2.79 million cases in India. Thus, rising cases of various infections are expected to boost the overall growth of the market. Asia-Pacific is followed by Europe, due to its large base of geriatric population and rising prevalence of infectious diseases in several countries of the region.

Competitive Landscape

The market studied is fragmented, owing to the presence of many small and large market players. Some of the market players are Astellas Pharma Inc., Baxter International, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Pharmaceuticals, Macleods Pharmaceuticals Ltd., Mankind Pharma, Merck & Co. Inc., Pfizer Inc., and Teva Pharmaceuticals.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Demand for Anti-microbials in Various Indications
    • 4.2.2 Rising Prevalence of Infectious Diseases
    • 4.2.3 Increasing Use of Combination Therapies
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Guidelines
    • 4.3.2 Weak Pipeline Molecules
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Generation
    • 5.1.1 First-generation
    • 5.1.2 Second-generation
    • 5.1.3 Third-generation
    • 5.1.4 Fourth-generation
    • 5.1.5 Fifth-generation
  • 5.2 By Prescription Type
    • 5.2.1 Prescription Drugs
    • 5.2.2 OTC Drugs
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aristo Pharmaceuticals Ltd
    • 6.1.2 Baxter International
    • 6.1.3 F. Hoffmann-La Roche AG
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Lupin Pharmaceuticals Inc.
    • 6.1.6 Macleods Pharmaceuticals Ltd
    • 6.1.7 Mankind Pharma
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Teva Pharmaceutical Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top